Neuropediatrics 2003; 34(3): 120-126
DOI: 10.1055/s-2003-41274
Original Article

Georg Thieme Verlag Stuttgart · New York

Glatiramer Acetate Treatment in Patients with Childhood and Juvenile Onset Multiple Sclerosis

B. Kornek[*] 1 , G. Bernert[*] 2 , C. Balassy 3 , J. Geldner 1 , D. Prayer 3 , M. Feucht 1
  • 1Department of Neuropsychiatry of Childhood and Adolescence, University of Vienna, Vienna, Austria
  • 2Department of Paediatrics, Division of Neuropediatrics, University of Vienna, Vienna, Austria
  • 3Department of Radiology, Division of Neuroradiology, University of Vienna, Vienna, Austria
Weitere Informationen

Publikationsverlauf

Received: June 7, 2002

Accepted after Revision: March 9, 2003

Publikationsdatum:
11. August 2003 (online)

Zoom Image

Abstract

Background

Recent data indicate that in multiple sclerosis disease onset before the age of 16 is more common than previously assumed. However, current therapeutic options are limited to the treatment of acute attacks in these patients. Glatiramer acetate has been successfully applied in adults with relapsing-remitting multiple sclerosis, but there are no data available about the use of glatiramer acetate in childhood and juvenile onset multiple sclerosis.

Methods

Seven patients with relapsing-remitting multiple sclerosis and disease onset between 9 and 16 years of age were treated with daily subcutaneous injection of 20 mg glatiramer acetate (Copaxone). Patients were followed for 24 months. Treatment was initiated in all patients before the age of 18.

Results

The use of glatiramer acetate in our cohort of early onset multiple sclerosis patients was safe and well tolerated. Two out of seven patients remained relapse-free during the two year period. Clinical disability as measured by the EDSS remained stable in three out of seven patients.

Conclusion

Due to the small number of patients the efficacy of the treatment has to be interpreted with caution. However, there might be a more pronounced treatment benefit in patients with low disability at treatment initiation and early treatment onset.